Immunohistochemistry typically reveals B-cell markers (e.g., CD20, BCL2), with negativity for markers such as CD5, CD10, and BCL6, which helps distinguish PCMZL from other cutaneous or systemic B-cell lymphomas [4,5,7,9,10]. This evidence concerns the gene CD5 and primary cutaneous marginal zone B-cell lymphoma.